Neurosense Therapeutics Ltd. failed to impress Wall Street with top-line data from its phase IIb study called Paradigm with PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib, in amyotrophic lateral sclerosis.

Virios Therapeutics Inc. said most likely COVID-19 had a hand in the phase IIb failure of IMC-1 (famciclovir + celecoxib), a dual COX-2/COX-1 inhibitor for treating fibromyalgia. The drug failed to hit statistical significance in dampening pain severity when compared to placebo (p=0.302).

A multicenter study led by scientists at Monash Institute of Pharmaceutical Sciences in Melbourne, Australia, has described a new mesenteric lymph vessel-based pathogenic mechanism, which was shown to contribute to visceral fat accumulation and insulin resistance in both mice and humans.